Fresenius Kabi

Fresenius Kabi AG
legal form	Corporation
founding	1999
Seat	Bad Homburg vor der Höhe , Hesse , Germany
management	Mats Henriksson
Number of employees	39,627 (December 31, 2019)
sales	EUR 6.919 billion (2019)
Branch	Pharmacy and Medical Devices
Website	www.fresenius-kabi.com
	As of December 31, 2019

The Fresenius Kabi AG , based in Bad Homburg is a global health company that provides medicines and medical devices for infusion, transfusion and clinical nutrition offering. Fresenius Kabi's products and services are used in the therapy and care of critically and chronically ill patients. The product portfolio includes generic drugs to be administered intravenously, infusion therapies, clinical nutrition and the associated medical technology products for application. In the area of transfusion medicine and cell therapy, Fresenius Kabi offers products for the extraction of blood components and for extracorporeal therapy procedures. In the biosimilars area, Fresenius Kabi focuses on products with a focus on oncology and autoimmune diseases.

Fresenius Kabi employs around 40,000 people worldwide and has a network of around 65 sales companies and around 65 production sites. In the 2019 financial year, the company achieved sales of more than 6.9 billion euros. Fresenius Kabi AG is a wholly-owned subsidiary of Fresenius SE & Co. KGaA .

Product portfolio

The extensive product portfolio for intravenous therapy of critically ill patients offers a wide range of generic intravenous drugs. The range includes drugs such as antibiotics, anesthetics, analgesics and drugs for oncology. The portfolio for infusion therapy includes various solutions for correcting disorders in the electrolyte or acid-base balance, volume replacement solutions and carrier solutions for compatible drugs. In clinical nutrition, Fresenius Kabi offers parenteral (intravenously administered) and enteral (sip and tube feedings that are administered via the gastrointestinal tract) nutrition products. In the field of medical devices, Fresenius Kabi has a comprehensive range of application technology and application systems for the infusion of generic drugs, infusion therapies and clinical nutrition. In the biosimilars segment, Fresenius Kabi focuses on products with a focus on autoimmune diseases and oncology. In the area of transfusion medicine and cell therapy, Fresenius Kabi offers products for the extraction of blood components and for extracorporeal therapy procedures.

history

Fresenius Kabi was founded in 1999 when the Fresenius Pharma division merged with the clinical nutrition business (Kabi) of the Swedish manufacturer Pharmacia & Upjohn . At that time, Kabi stood for Kärnbolaget Aktiebolag Biokemisk Industri , which was still used in the advertised form until 1951.

In 2000, Fresenius Kabi opened up new growth markets in Asia, Africa and Latin America. The company strengthened its market position with acquisitions in South Africa and the Czech Republic and a joint venture in Australia in 2004.

In 2005, Fresenius Kabi bought the Portuguese pharmaceutical company Labesfal (Laboratorio de Especialidades Farmaceuticas Almiro SA) from Campo de Besteiros . In the same year, the takeover of the German medical device manufacturer Clinico GmbH (infusion and nutrition pumps) from Bad Hersfeld in Hesse followed.

In 2006 Fresenius Kabi acquired the Argentine pharmaceutical company Laboratorios Filaxis SA , Buenos Aires.

In 2007, further takeovers were made in order to have a stronger presence in the global market for infusion therapy: the Japanese Kyorin Pharmaceuticals Co. Ltd. , Tokyo, the Chilean Laboratorio Sanderson SA and the Italian antibiotics manufacturer Ribbon SrL, Milan. In the same year, Nestlé SA took over the enteral nutrition business in Spain and France.

In 2008 Fresenius Kabi acquired the Indian generics manufacturer Dabur Pharma Ltd. In summer 2008, Fresenius SE & Co. KGaA (formerly Fresenius SE) bought the US pharmaceutical company APP Pharmaceuticals from Schaumburg , Illinois (USA), which was founded in 1996 and manufactures intravenous generics in Illinois, New York. The purchase price for Fresenius, including the assumption of debt and special payments, was up to US $ 5.6 billion.

At the end of 2012, Fresenius Kabi acquired the transfusion technology provider Fenwal Inc. , Lake Zurich, Illinois (USA) and thus achieved a leading position worldwide in transfusion technology with a comprehensive product portfolio for the collection and processing of blood components and for the therapeutic treatment of patient's blood using apheresis procedures.

In January 2016, Fresenius Kabi acquired a US manufacturing facility and portfolio of seven IV drugs in pre-filled syringes that were sold by Becton, Dickinson and Company (“BD”), a US medical technology company.

After the use of the narcotic propofol for executions of prisoners sentenced to death was considered in the United States , Fresenius Kabi, as the manufacturer of the product, tried to prevent this by means of trade restrictions .

In 2017, Fresenius Kabi took over the biosimilars business from Merck . The intention to take over the US pharmaceutical company Akorn was also announced , but this did not materialize.

In 2019, Fresenius Kabi launched its first biosimilar product in Europe.

Logistics centers

Berlin branch in Potsdam
Friedberg and HemoCare branches in Friedberg
Hanover branch in Langenhagen
Munich branch in Garching-Hochbrück
West branch in Hilden
Stuttgart branch in Friolzheim
Bad Homburg order control center and order entry clinic in Bad Homburg vor der Höhe
Distribution and high-bay warehouse in Friedberg (Hessen)

Competitors in Germany

In the area of enteral nutrition: Numico (to the Danone Group), sales in Germany by Pfrimmer Nutricia GmbH, Erlangen
In the area of infusion therapy and parenteral nutrition: B. Braun Melsungen , Baxter International and PlasmaSelect AG with its subsidiary DeltaSelect GmbH , Munich and only in the area of infusion solutions, Serag-Wiessner KG , Naila.

Web links

Individual evidence

↑ Imprint. Retrieved March 18, 2020 .
↑ ^a ^b Key Figures. Fresenius Kabi AG, accessed on March 18, 2020 .
↑ About us - Key Figures. Retrieved March 18, 2020 .
^ Fresenius Kabi - Business Fields. Retrieved March 18, 2020 (English).
↑ Fresenius Kabi Launches Biosimilar Adalimumab IDACIO In Germany. In: Biosimilardevelopment.com. May 3, 2019, accessed on March 18, 2020 .
↑ Fresenius Kabi - about us. In: en. Retrieved March 18, 2020 .
↑ ^a ^b ^c company history. Retrieved March 18, 2020 (English).
↑ WDH / Fresenius wants to further reduce short-term debt with bond June 3, 2009
^ Company Profile from Hoover's: APP Pharmaceuticals, LLC
^ H. Haarhoff, R. Reichstein: Fresenius restricts propofol sales: "Death cocktails" are becoming scarce. In: taz.de. September 11, 2012, accessed September 11, 2012 .

[Fresenius-1] Imprint. Retrieved March 18, 2020 .

[gb-2] Key Figures. Fresenius Kabi AG, accessed on March 18, 2020 .

[3] About us - Key Figures. Retrieved March 18, 2020 .

[4] Fresenius Kabi - Business Fields. Retrieved March 18, 2020 (English).

[5] Fresenius Kabi Launches Biosimilar Adalimumab IDACIO In Germany. In: Biosimilardevelopment.com. May 3, 2019, accessed on March 18, 2020 .

[6] Fresenius Kabi - about us. In: en. Retrieved March 18, 2020 .

[:0-7] company history. Retrieved March 18, 2020 (English).

[8] WDH / Fresenius wants to further reduce short-term debt with bond June 3, 2009

[9] Company Profile from Hoover's: APP Pharmaceuticals, LLC

[10] H. Haarhoff, R. Reichstein: Fresenius restricts propofol sales: "Death cocktails" are becoming scarce. In: taz.de. September 11, 2012, accessed September 11, 2012 .